The Problem You Are Facing
You are a pharma leader and you know you should be visible on LinkedIn.
You have read the data. Personal profiles generate eight times more engagement than company pages posting identical content. Executive content costs seventy-three percent less per qualified engagement than company-sponsored content, with four times the conversion rate. Professionals with active personal brands receive forty-seven percent more inbound opportunities, including partnership inquiries, speaking invitations, and inbound client interest. LinkedIn outperforms Facebook and X by two hundred and seventy-seven percent on B2B lead generation. Four hundred and eighty-nine of the top five hundred LinkedIn newsletters belong to individuals, not companies.
You are not on the list of those individuals.
It is not because you do not have anything to say. You have spent fifteen to twenty years inside pharma. You have run launches, sat through MLR reviews, watched commercial strategies fail and succeed, navigated regulatory crises, and seen exactly how the industry actually works. The expertise is real.
The constraint is time. The research published this year is consistent on this point: the biggest pushback from executives and founders on LinkedIn is time, and the second is not knowing what to say next. You are not unusual. You are normal. Normal is the problem.
The traditional answer to this is to hire a ghostwriter. The traditional ghostwriter for a pharma executive does one of two things. Either they write generic LinkedIn content that could have come from anyone in any industry, because they do not actually understand pharma. Or they write competent industry content but generate two to four posts a month at a fee structure that makes the entire engagement uneconomic for anyone outside a top-twenty executive role.
Neither answer scales. Neither answer produces the volume of content the LinkedIn algorithm actually rewards. Neither answer differentiates you in a feed already full of pharma consultants and KOLs who are publishing every week.
There is a third answer. It is an AI content system, designed specifically for pharma, that produces a full week of research-backed, sourced, voice-consistent content in approximately four hours of your time per week.
I built it for myself. I now build it for other pharma leaders who want the same capability.
The System I Built
I publish weekly on pharma, AI, and the future of life sciences. Long-form blog articles. LinkedIn long-form text posts. Carousel documents. Visual hook graphics. The content is sourced. Every claim is verified. Every post is voice-consistent and structurally tuned to LinkedIn's distribution model.
The output looks like the work of a content team. The system that produces it is a single integrated AI workflow with four components.
The first is the research engine. Before any post is drafted, the system runs verified web research across three to five parallel queries on the topic, pulling primary sources, academic papers, regulator publications, industry analyst reports, and recent enforcement actions. The output is a sourced research brief, with every claim mapped to a primary source URL, and a stat audit table that flags claims as verified, illustrative, or unsourced. The brief is what every downstream draft references. Hallucination is structurally constrained because the model is not generating claims, it is selecting and structuring claims from the brief.
The second is the voice layer. The system has a captured profile of your voice: your sentence length, your phrasing patterns, your stance, your CTA style, your structural preferences. Every draft is generated inside that profile. The model does not write in a generic LinkedIn voice. It writes in your voice. The captured profile is built in a one-hour intake interview and refined over the first three weeks of operation.
The third is the format layer. The system knows what a LinkedIn long-form text post looks like at maximum reach (1,800 to 2,100 words on the blog version, under 3,000 characters on the LinkedIn version, posted Tuesday through Thursday between 9am and noon for the seventy percent reach lift the algorithm gives early-window content). It knows what a carousel looks like (hook-stat slide, problem slides, solution slide, comparison slide, CTA slide). It knows what a document PDF looks like for LinkedIn's document format. It produces every format from the same underlying research brief.
The fourth is the compliance layer. The system is pharma-aware. It knows the difference between disease-awareness content and promotional content. It knows when a claim needs a primary source. It knows when content drifts toward off-label promotion. It will not generate unsubstantiated efficacy claims, comparative claims, or off-label use suggestions. For pharma leaders who care about MLR-friendly content production at scale, this is the single hardest layer to build and the most important.
The four components run as one workflow. Topic in, sourced research brief, voice-consistent drafts in every format, ready for your review.
What a Week of Output Looks Like
A typical week of output from the system, for a pharma leader running on the four-hour cadence:
One long-form blog article of 1,800 to 2,500 words, fully sourced, SEO-optimized, with a Sanity-ready meta package (title, slug, excerpt, meta title and description, keywords, alt text, image prompt, source list, stat audit).
One LinkedIn long-form text post, under 3,000 characters, adapted from the blog article for LinkedIn distribution.
One carousel document with eight to ten slides, designed for LinkedIn's document format, with the same research foundation as the long-form post.
One cover image prompt for each post, written to spec for whichever image generator or designer you use.
Three to four short reactive posts during the week, anchored to industry news, regulator publications, or competitor announcements, drafted in your voice.
Optional newsletter draft if you are running a LinkedIn newsletter.
Total volume per week: roughly five to seven distinct published assets, plus the structural research and source library that supports them.
Total time from you: approximately four hours, distributed as one ninety-minute editorial direction session, one one-hour review session midweek, and ninety minutes of approve-edit-publish on the final outputs.
Why This Is Different from a Generic Ghostwriter or a Generic Content Tool
Three reasons.
First, the research engine. Every other content tool I have used either skips the research step entirely (which is why so much LinkedIn content reads like opinion without evidence) or treats research as an optional add-on. The system I built treats the sourced research brief as the foundation. Nothing gets drafted without a brief. Nothing in the brief is unsourced. The audit table is non-negotiable.
Second, the pharma compliance awareness. A generic AI content tool will happily produce comparative efficacy claims, off-label suggestions, and unsubstantiated benefit statements because it does not know that those produce FDA warning letters in pharma. The system I built does. That is the layer that took the longest to engineer and that no off-the-shelf tool currently provides.
Third, the voice layer is calibrated, not templated. Most AI content tools impose a generic LinkedIn voice ("punchy hook, three-bullet middle, motivational close") that is recognizable within ten seconds. The system I built does not. The voice profile is captured per individual, tested against your existing writing, and refined over the first three weeks until the output is indistinguishable from work you would produce yourself if you had the time.
What You Get
The system is deployed as a four-week onboarding, followed by ongoing operation.
In the onboarding you get:
- A one-hour voice intake interview, plus analysis of your existing writing samples and posts to calibrate the voice profile
- A pharma-specific topic backlog of forty to sixty viable post angles built around your positioning, your audience, and your business goals
- The full system stood up: research engine, voice layer, format layer, compliance layer
- The first four weeks of content produced and published, with weekly review cycles to refine voice, format preferences, and topic selection
In ongoing operation you get:
- Five to seven published assets per week, with the time investment from you held to approximately four hours
- Monthly performance review on engagement, inbound opportunities, and topic performance
- Quarterly voice and topic recalibration based on what is working
Performance envelope based on the system architecture and the underlying LinkedIn data:
- Three to five times the content output of a traditional executive content workflow at one-third the time investment
- Personal profile engagement at the eight-times multiplier over company-page equivalent content (per LinkedIn data)
- Inbound opportunities (speaking, partnership, consulting inquiries) measurably higher within ninety days
- Content fully sourced, fully voice-consistent, and MLR-friendly enough to survive any compliance review your role requires
These are the targets the system is designed to hit. Your specific results depend on the depth of your domain expertise, the clarity of your positioning, your willingness to publish under your own name, and how consistently you do the four-hour review cadence.
How to Start
The next step is a thirty-minute content system call.
You walk me through your current LinkedIn presence, your visibility goals, the audience you want to reach, and the business outcomes you want the content to drive. I walk you through what the system would look like calibrated to your voice, your topics, your audience, and your weekly cadence.
The output of the call is a one-page content system spec specific to your situation: the topic backlog framework, the voice profile dimensions, the format mix, the publishing cadence, and what a four-week onboarding would look like for you.
No procurement process required for the call. No NDA on the way in.
If you are a pharma leader who has been telling yourself "I should be on LinkedIn more" for the last twelve months, this is the call.
Book a 30-minute content system call →
The pharma leaders who get visible on LinkedIn in the next twelve months will own a disproportionate share of the inbound opportunity, the speaking circuit, and the consulting market for the rest of the decade. The ones who do not will keep wishing they had time, while their peers publish past them every Tuesday morning.
